# Can we reduce HIV confirmation testing based on the HIV screen semi-quantitative test result?

Fien Vanroye<sup>1</sup>, Laurent Debaisieux<sup>2</sup>, Virginie Mortier<sup>3</sup>, Karolien Stoffels<sup>4</sup>, Dolores Vaira<sup>5</sup>, S. Van den Wijngaert<sup>4</sup>, Melissa Depypere<sup>6</sup>, Chris Verhofstede<sup>3</sup>, Dorien Van den Bossche<sup>1</sup>

<sup>1</sup> ARL, Clinical Reference Laboratory, Institute for Tropical Medicine, Antwerp, Belgium; <sup>3</sup> ARL, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium; <sup>4</sup> ARL, Centre Hospitalier Universitaire St. Pierre, Brussels, Belgium; <sup>5</sup> ARL, Centre Hospitalier Universiteit Leuven, University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Katholieke Universiteit Leuven, University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier Universiteit Leuven, University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier Universiteit Leuven, University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitalier University hospitals Leuven, Belgium; <sup>6</sup> ARL, Centre Hospitals Leuv

# Introduction

HIV confirmation testing is time-consuming, assays are expensive and often batched which delays result reporting. For other serology assays (e.g., HCV) confirmation testing is no longer required when the result of the screening assay is above a certain cut-off. Data from six Belgian Aids Reference Laboratories (ARL) (ULB, UGent, STP, ULiège, KUL and ITM) covering various 4<sup>th</sup> and 5<sup>th</sup> generation HIV Enzyme Immunoassay (EIA) were compiled. The aim was to investigate whether we can set a cutoff for these different HIV screening assays above which the HIV infection can be confirmed without further testing. Additionally, for 5<sup>th</sup> generation assays, it was verified if the separate Ag result could reliably indicate an HIV seroconversion at a certain cut-off.

# Architect HIV Ag/Ab Combo assay (Abbott) (n = 44072) 1600 Cutoff = 1,0 1400 1200 1000 **ヒ**40 800 600 400 200 Elecsys HIV combi PT Ab/Ag (Roche Diagnostics) (n = 1019) 6000 700 Cutoff = 1,0 5000 4000 3000 2000 200 1000 100 Genscreen Ultra HIV Ag/Ab (Bio-Rad) (n = 29157)

The risk of mis-diagnosing a person as HIV positive can underminate results. Due to the appearance of undeniable outliers and the many indeterminate results with high test values, HIV confirmation testing remains necessary as infection can never be reliably confirmed based on the screening result. Also, differentiation between HIV-1 and HIV-2 cannot be established without confirmation tests does not allow to conclude acute HIV infection and additional tests (e.g., viral load, other p24 Ag assays) are needed due to aspecific cross-reactivity with high Ag values. This data analysis provides insight into the semi-quantitative screening assay results and can be of aid for the ARLs to interpret complicated confirmation patterns. An EIA screening test alone cannot be used for a diagnostic conclusion without additional tests. The cut-offs set by the commercial kit cannot be set higher as low values are observed for HIV infected patients. Contact person: fvanroye@itg.be

All assays used in the ARLs are categorized in 2 different groups (4<sup>th</sup> generation assay detecting antigen and antibodies (Ag/Ab) at the same time and 5<sup>th</sup> generation assay detecting Ag and Ab separately). All samples sent to ARLs for screening and/or confirmation testing from 2016 to 2020 were assigned to 4 different groups:

**Ratios** and **test values** (Ab, Ag, Ab/Ag) for all samples per test were analyzed in a **boxplot for comparison between groups**.

## **Results 4<sup>th</sup> generation test**

Vidas HIV Duo Quick Ag/Ab (Biomérieux) (n = 35054)



Vitros HIV Combo Test Ag/Ab (Ortho Clinical Diagnostics) (n = 4281)





### Conclusion

## Methods

• HIV-1 or HIV-2 positive infected patient : reactive Ag/Ab screening test and HIV-1 positive Ab or HIV-2 positive Ab confirmation test • HIV indeterminate II: reactive or negative screening Ag/Ab test and indeterminate Ab confirmation or blot test • HIV seroconverter - : reactive Ag/Ab screening test, positive p24 antigen test and negative Ab confirmation • HIV negative patient : negative or reactive screening Ag/Ab test and negative Ab confirmation



